The N-Terminal domain of SIRT1 is a positive regulator of endogenous SIRT1-dependent deacetylation and transcriptional outputs

Fiorella Ghisays  
Washington University School of Medicine in St. Louis

Cynthia S. Brace  
Washington University School of Medicine in St. Louis

Shawn M. Yackly  
Washington University School of Medicine in St. Louis

Hyock Joo Kwon  
Washington University School of Medicine in St. Louis

Kathryn F. Mills  
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Ghisays, Fiorella; Brace, Cynthia S.; Yackly, Shawn M.; Kwon, Hyock Joo; Mills, Kathryn F.; Kashentseva, Elena; Dmitriev, Igor P.; Curiel, David T.; Imai, Shin-ichiro; and Ellenberger, Tom, “The N-Terminal domain of SIRT1 is a positive regulator of endogenous SIRT1-dependent deacetylation and transcriptional outputs.” Cell Reports.10,10. 1665-1673. (2015).  
https://digitalcommons.wustl.edu/open_access_pubs/3802

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
The N-Terminal Domain of SIRT1 Is a Positive Regulator of Endogenous SIRT1-Dependent Deacetylation and Transcriptional Outputs

Graphical Abstract

Highlights
- The SIRT1 N-terminal domain regulates acetylation of NF-κB p65 and p53
- NTERM physically interacts with SIRT1 and promotes binding to NF-κB p65
- Two NTERM motifs interact with each other and contribute to these effects
- One peptide motif lowers fasting glucose and improves glucose tolerance in vivo

Authors
Fiorella Ghisays, Cynthia S. Brace, ..., Shin-ichiro Imai, Tom Ellenberger

Correspondence
imaishin@wustl.edu (S.I.), tome@wustl.edu (T.E.)

In Brief
The NAD⁺-dependent protein deacetylase SIRT1 regulates energy metabolism, responses to stress, and aging by deacetylating proteins, including histones and transcription factors. Ghisays et al. show that the catalytically inactive, N-terminal domain of SIRT1 regulates deacetylation activity in cells and improves glucose metabolism in mice, with implications for SIRT1-based therapeutics.
The N-Terminal Domain of SIRT1 Is a Positive Regulator of Endogenous SIRT1-Dependent Deacetylation and Transcriptional Outputs


SUMMARY

The NAD+-dependent protein deacetylase SIRT1 regulates energy metabolism, responses to stress, and aging by deacetylating many different proteins, including histones and transcription factors. The mechanisms controlling SIRT1 enzymatic activity are complex and incompletely characterized, yet essential for understanding how to develop therapeutics that target SIRT1. Here, we demonstrate that the N-terminal domain of SIRT1 (NTERM) can trans-activate deacetylation activity by physically interacting with endogenous SIRT1 and promoting its association with the deacetylation substrate NF-κB p65. Two motifs within the NTERM domain contribute to activation of SIRT1-dependent activities, and expression of one of these motifs in mice is sufficient to lower fasting glucose levels and improve glucose tolerance in a manner similar to overexpression of SIRT1. Our results provide insights into the regulation of SIRT1 activity and a rationale for pharmacological control of SIRT1-dependent activities.

INTRODUCTION

The NAD+-dependent deacetylase SIRT1 is a modifier of transcriptional outputs that regulate lipid and glucose metabolism, inflammatory signaling, and programmed cell death through its effects on chromatin structure and transcription factor activity (Haigis and Sinclair, 2010; Satoh et al., 2011; Sinclair and Guarente, 2014). Increased SIRT1 activity enhances mitochondrial biogenesis, suppresses inflammation, prevents apoptosis following DNA damage, and generally promotes cell survival in degenerative conditions (Banks et al., 2008; Chen et al., 2005; Jiang et al., 2012; Kang et al., 2009; Kim et al., 2007a; Pfluger et al., 2008; Yuan et al., 2011). The deacetylase activity of SIRT1 is limited by cellular levels of NAD+, which fluctuate in response to changing rates of NAD+ biosynthesis and consumption (Houtkooper et al., 2010; Nakahata et al., 2009; Ramsey et al., 2009; Revollo et al., 2004). Several protein regulators of SIRT1 also have been identified, including the positive regulators AROS (active regulator of SIRT1) and Necdin (Hasegawa and Yoshikawa, 2008; Kim et al., 2008) and an inhibitory protein DBC1 (deleted in breast cancer 1) (Kim et al., 2008; Zhao et al., 2008). Phosphorylation of SIRT1 also can affect deacetylation activity by regulating its interactions with protein substrates (Back et al., 2011; Kang et al., 2009; Nasrin et al., 2009; Nin et al., 2012; Sasaki et al., 2008). Additional posttranslational modifications of SIRT1, including methylation, sumoylation, and nitrosylation, have been reported (Flick and Lüscher, 2012; Revollo and Li, 2013) and remain to be functionally characterized. Expression of SIRT1 increases following DNA damage (Kang et al., 2009; Wang et al., 2006, 2008; Yuan et al., 2012), and a growing list of transcription factors have been shown to increase or decrease Sirt1 expression (Revollo and Li, 2013). It is well established that SIRT1 is broadly involved with regulating cellular metabolism and stress-dependent signaling. However, the molecular mechanisms that govern substrate selection by SIRT1 (Blander et al., 2005; Pan et al., 2012) and regulate its deacetylase activity (Cantó and Auwerx, 2012; Sinclair and Guarente, 2014) are poorly understood.

Seven mammalian paralogs of the founder protein Sir2 in yeast, SIRT1 through SIRT7, share a conserved catalytic core but have distinctive biological activities that are ascribed to the nonconserved, flanking regions of each enzyme (Satoh et al., 2011). The ESA motif (Essential for SIRT1 Deacetylase Activity; Figure 1A), located C-terminal to the catalytic core of SIRT1, is suggested to physically interact with the core domain to enable deacetylase activity (Kang et al., 2011). SIRT1 also has a large, N-terminally flanking domain that interacts with AROS (Kim et al., 2007b), the active regulator of SIRT1, as well as small molecule activators of deacetylase activity (Milne et al., 2007). The numerous sites of posttranslational modification located in the N-terminal domain of SIRT1 and its interactions with protein and small molecule activators of deacetylase activity together suggested this domain functions as a regulator of SIRT1-dependent activities. Here, we report that overexpression of the N-terminal domain of SIRT1 (Figure 1A; NTERM, residues 1–221)
activates SIRT1-dependent activities in mammalian cells. This trans-activation of SIRT1 function is mediated by two separate motifs within NTERM that interact with each other and stabilize complexes of SIRT1 with deacetylation substrates. Mice transduced with an adenovirus expressing one of these NTERM motifs showed reduced fasting glucose levels and enhanced glucose tolerance, similar to mice overexpressing full-length SIRT1. These findings suggest a mechanistic framework for examining substrate selection and the regulation of SIRT1 enzymatic activity.

RESULTS

NTERM Expression Increases SIRT1-Dependent Activities

We expressed the NTERM domain of SIRT1 (Figure 1A) in HepG2 cells to examine the effects on protein acetylation and gene expression linked to SIRT1 enzymatic activity. Acetylation of Lys310 in the p65 subunit of NF-κB, a well-characterized target of SIRT1 deacetylation (Ghosh et al., 2007; Yeung et al., 2004), was monitored in cells overexpressing NTERM. Expression of the catalytically inactive NTERM domain lowers acetyl-p65 to the same level as overexpression of enzymatically active SIRT1 (Figure S1). The levels of acetyl-p65 were quantitated for experiments in cells transfected with 1 μg of each plasmid including SIRT1, CTERM, NTERM, or empty vector. The means and SEs are shown for four experiments normalized to total NF-κB and expressed as a percentage of the acetylated NF-κB in control cells.

Figure 1. Expression of NTERM Activates Endogenous SIRT1

(A) (Top) Schematic representation of SIRT1 N-terminal, catalytic core, and C-terminal domains. (Bottom) Peptides spanning the NTERM domain and including the activating motifs A and B (dark brown) were expressed in cells to monitor effects on p65 acetylation (Figure 2). A region of predicted disorder (light brown) separates motifs A and B. A model depicting the interaction of NTERM motifs A and B, functioning in trans as a dimerization interface (dimer, left side) or in cis to stabilize the fold of the NTERM domain (monomer, right side).

(B) Acetylation of NF-κB p65 was monitored by western blotting whole-cell extracts from HepG2 cells co-expressing SIRT1, the NTERM domain, or CTERM. Expression of the catalytically inactive NTERM domain lowers acetyl-p65 to the same level as overexpression of enzymatically active SIRT1 (Figure S1).

(C) The levels of acetyl-p65 were quantitated for experiments in cells transfected with 1 μg of each plasmid including SIRT1, CTERM, NTERM, or empty vector. The means and SEs are shown for four experiments normalized to total NF-κB and expressed as a percentage of the acetylated NF-κB in control cells.

(D) NTERM overexpression decreases acetylation of p65 NF-κB levels and this effect is antagonized by the SIRT1 inhibitor EX-527. HepG2 cells were transfected with NTERM (top) or SIRT1 (bottom) and grown for 48 hr in the presence of DMSO (2%) or EX-527 (10 or 25 μM) prior to western blotting. NF-κB acetylation increases with increasing concentrations of the SIRT1 inhibitor EX-527 in HepG2 cells expressing NTERM (top) or SIRT1 (bottom), indicating the effect of NTERM overexpression is dependent upon SIRT1 enzymatic activity.

(E) Pepck expression increases significantly in mouse primary hepatocytes expressing NTERM, similar to the effects of SIRT1 overexpression. The NTERM construct with the native nuclear localization signal (NLS) behaved similarly to the NTERM-NLS construct with an additional NLS added to its N terminus. Pepck transcripts were quantitated by qRT-PCR. The means and SEs are shown for four independent experiments.
that cellular levels of acetyl-p53 were coordinately decreased with increasing NTERM expression (Figures S1C and S1D).

The cellular concentration of SIRT1 protein was unaffected by overexpression of NTERM (Figure S1E), suggesting that NTERM functions by increasing the enzymatic activity of endogenous SIRT1. Consistent with this mechanism, the small molecule SIRT1 inhibitor EX-527 antagonized the effect of NTERM and returned p65 acetylation to control levels (Figure 1D). The expression of Pepck (phosphoenolpyruvate carboxykinase) mRNA was increased by NTERM overexpression in primary hepatocytes (Figure 1E), another hallmark of increased SIRT1 activity. Together, these molecular readouts indicate a widespread activation of SIRT1-dependent processes (Grimm et al., 2011; Rodgers et al., 2005) concordant with NTERM overexpression.

The Recombinant NTERM Domain Interacts with SIRT1
To examine the mechanism of this change in SIRT1-dependent processes, we next measured the physical interactions of SIRT1 with NTERM and deacetylation substrates. Myc-tagged SIRT1 was efficiently co-immunoprecipitated with HA-tagged NTERM in HepG2 cells, and more SIRT1 is pulled down in the complex with HA-NTERM as SIRT1 expression is increased.

Two NTERM Motifs Independently Stimulate SIRT1 Activities
The amino acid sequence of NTERM consists of two regions of predicted α-helical character that are separated by a low-complexity sequence indicative of disorder (Figure 1A). Intrinsically disordered regions of proteins are frequently involved in protein-protein interactions (Mészáros et al., 2011). Deletion mutagenesis identified two regions within NTERM that could trans-activate SIRT1 (Figure 2). A series of Myc-tagged peptides was expressed in HepG2 cells (Figure 1A) spanning NTERM residues 1–26 (peptide b), 1–52 (peptide c), 1–108 (peptide d), 1–163 (peptide e), 27–52 (peptide f), 52–108 (peptide g), 52–221 (peptide h), 108–221 (peptide i), 108–163 (peptide j), and 163–221 (peptide k). Most of these constructs were abundantly
expressed, although we could not verify the expression of short peptides b and f by western blot analysis (Figure 2B). A pattern emerged in which peptides from two different regions of NTERM significantly decreased the acetylation of p65 NF-κB (Figures 2B and 2C). Strongly activating peptides (c, e, and h) decreased p65 acetylation to 23%–34% of that seen in cells transfected with vector only. Peptides b, d, i, and k showed intermediate levels of activity, decreasing p65 acetylation levels to 45%–62% of control values, whereas constructs f, g, and j had no significant effect on p65 acetylation. The results suggest that NTERM residues 1–52 (motif A; Figure 1A) and 163–221 (motif B) comprise independent motifs that when overexpressed can trans-activate SIRT1-dependent cellular activities (Figure 2C). Notably, these motifs correspond to the regions of NTERM that are predicted to be α-helical. Motif B overlaps with a region that is essential for activation of SIRT1 enzymatic activity by small molecule agonists (Hubbard et al., 2013; Milne et al., 2007).

We considered the possibility that helical motifs A and B might interact with each other either in trans or within the native fold of the NTERM domain (Figure 1A). The HA-tagged motif A peptide was co-expressed with a series of Myc-tagged, N-terminally truncated SIRT1 proteins and then immunoprecipitated with an anti-HA antibody. Motif A efficiently co-immunoprecipitated Myc-tagged SIRT1, SIRT1Δ52, and SIRT1Δ108 proteins, and exhibited a weak interaction with SIRT1Δ163 (Figure 2D). However, the motif A peptide failed to interact with the SIRT1Δ221 protein lacking motif B (Figure 2D). The motif B peptide (k) bound nonspecifically to the beads and could not be tested for interactions by itself, although expression of this peptide consistently decreased acetylation levels of NF-κB (Figure 2B).

It was reported that recombinant SIRT1 dimerizes, and that dimerization is abolished by the phosphomimetic mutation Thr222Glu (Guo et al., 2012). However, we and others have examined the oligomeric state of recombinant SIRT1 protein purified from E. coli and find no evidence of dimer formation (Lakshminarasimhan et al., 2013b; Figure S3). Sedimentation equilibrium experiments conducted over a range of SIRT1 concentrations (5–50 μM) and g-forces indicated that recombinant SIRT1 is monomeric with a buoyant mass of 90 kDa, consistent with the calculated mass of 86 kDa (Figure S3A). The amino acid sequence of the NTERM domain is predicted to be disordered (Dunker et al., 2008), and correspondingly, the NTERM domain contributes to interactions with substrates for deacetylation and with protein and small molecule activators of SIRT1 activity (Kim et al., 2007b; Milne et al., 2007; Sinclair and Guarente, 2014).

Overexpression of the NTERM constructs allows the detection of interactions in trans between motifs A and B (Figures 2B and S2A) and the self-association of NTERM domains (Figure S2B). Co-immunoprecipitation of NTERM domains may require an elevated protein concentration, posttranslational modifications, and/or partner proteins that are absent from in vitro studies of recombinant SIRT1 protein. The results with purified, recombinant SIRT1 protein do not support a dimerization model. Instead, motifs A and B may pack together to stabilize the native fold of SIRT1 monomers (Figure 1A).

The NTERM Domain Promotes the Interaction of SIRT1 with Substrates

NTERM overexpression causes a decrease in levels of acetyl-p65 NF-κB (Figure 1B) that is suggestive of enhanced SIRT1 activity, perhaps by promoting enzyme-substrate interactions. To examine this hypothesis, endogenous SIRT1 was pulled down from extracts of HEK293 cells overexpressing the deacetylation substrate NF-κB p65 that were co-transfected with increasing amounts of NTERM. SIRT1 was immunoprecipitated with an antibody directed at its C terminus, and the resulting precipitates contained a ternary complex of SIRT1, p65, and NTERM. The amount of p65 in the complex increased concurrently with increased expression of NTERM (Figure 3A), suggesting that the NTERM domain does indeed promote the association of SIRT1 with the NF-κB p65 substrate. Reciprocal pull-downs confirmed the formation of a ternary p65/SIRT1/TERM complex using antibodies directed at NTERM (Figure 3B) or p65 (not shown).

To further probe the components of the SIRT1/TERM/p65 complex, we attempted to measure the amounts of acetylated and deacetylated p65 in the complex. To our surprise, p65 in the complex was completely deacetylated, suggesting that, once recruited into the complex, p65 is efficiently deacetylated and remains complexed to SIRT1 (Figure 3C). Consistent with these findings, the comparison of the deacetylation activities of full-length SIRT1 and SIRT1Δ221 on an in vitro acetylated p65 (1–325) substrate showed that the N-terminal domain of SIRT1 significantly enhances the rate of NF-κB p65 deacetylation in vitro (Figure 3D). Because both SIRT1 and SIRT1Δ221 exhibit similar kinetics toward a peptide substrate (not shown), these results suggest that the NTERM domain likely enhances deacetylation activity toward protein substrates by promoting the enzyme-substrate interaction.

The co-immunoprecipitation of the NTERM domain with the enzyme-substrate complex is consistent with a direct effect of NTERM on the substrate-binding activity of SIRT1. Alternatively, the overexpressed NTERM domain could sequester a negative regulator of SIRT1, such as the DBC1 protein, a competitive inhibitor of SIRT1 substrate-binding activity (Kim et al., 2008; Zhao et al., 2008). In this scenario, a physical interaction between NTERM and DBC1 would antagonize DBC1-dependent inhibition of SIRT1. We examined this hypothesis by co-expressing FLAG-tagged DBC1 and HA-tagged NTERM proteins in...
HEK293 cells and pulling down the NTERM domain with an anti-HA antibody. DBC1 was efficiently co-immunoprecipitated by NTERM (Figure S4A), and the reciprocal immunoprecipitation confirmed this interaction (Figure S4B). The DBC1 binding site previously was localized to the catalytic core of SIRT1 (Kim et al., 2008; Zhao et al., 2008). However, protein constructs described as the catalytic core in these studies included all (Kim et al., 2008) or part of (Zhao et al., 2008) the region we have defined as motif B of the NTERM domain. The NTERM domain of SIRT1 is sufficient for interaction with DBC1 (Figure S4B), and a SIRT1 deletion mutant lacking the NTERM domain does not interact with DBC1 (Figure S4C). Constructs that include motif B (residues 163–221; Figure 1A) also bind to DBC1 (Figure S4D), whereas the motif A peptide (residues 1–52) does not bind (Figure S4D).

Although overexpression of DBC1 caused a modest increase in acetyl-p53 levels, this effect was overcome by low-level expression of the NTERM domain (Figure S4E). Increasing the level of DBC1 expression did not antagonize the effect of NTERM on acetyl-p53 levels (Figure S4E). The interaction of DBC1 with SIRT1 is regulated by phosphorylation of both proteins (Nin et al., 2012; Yuan et al., 2012), and DBC1 may not be the primary determinant of SIRT1 activity in HepG2 cells under our experimental conditions. Other investigators have similarly reported that DBC1 does not consistently function as an inhibitor of SIRT1 activity in every cell line tested (Bae et al., 2012). The co-immunoprecipitation of NTERM and SIRT1 (Figure 2A) is consistent with a direct effect of the NTERM domain on the substrate-binding and enzymatic activities of SIRT1.

The Motif A Peptide Improves Glucose Metabolism in Mice

To examine the metabolic effects of NTERM expression in vivo, we constructed recombinant adenoviruses expressing SIRT1 and the motif A peptide (residues 1–52). Despite repeated attempts, we were unable to recover virus from an expression construct encoding the NTERM domain. Male C57BL/6 mice at approximately 2 months of age were infected with the other two recombinant viruses by tail vein injection, and overexpression of SIRT1 and the motif A peptide were confirmed 4 days post-infection by western blot analysis (Figure 4A). In agreement with previous reports (Rodgers and Puigserver, 2007; Rodgers et al., 2005), animals overexpressing SIRT1 had lower fasting glucose levels (Figure 4B) and significantly improved glucose tolerance measured by an intraperitoneal glucose tolerance test (IPGTT) (Figure 4C). Remarkably, overexpression of the motif A peptide had a similar effect of reducing fasting glucose levels and improving glucose tolerance in comparison to control animals overexpressing the GFP (Figures 4B and 4C). Insulin levels measured during the IPGTT were similar for the control animals and those expressing SIRT1 than by SIRT1(S221) lacking the NTERM domain. The means and SEs of three experiments are shown, after normalization to the activity of SIRT1.

![Figure 3. NTERM Enhances the Interaction of SIRT1 with Its Substrate NF-κB p65](image)
DISCUSSION

SIRT1 broadly regulates cellular metabolism, growth, and responses to stress by deacetylating transcription factors and histones, yet we have limited knowledge of mechanisms governing substrate selection by SIRT1 and the control of deacetylation activity (Haigis and Sinclair, 2010; Satoh et al., 2011; Sinclair and Guarente, 2014). Acetyl-lysine-containing peptides are promiscuously deacetylated in vitro by SIRT1 with little sequence selectivity (Blander et al., 2005; Lakshminarasimhan et al., 2013a), suggesting that additional binding interactions with protein substrates contribute to the biological specificity of deacetylation in a cellular context. Here we identify protein interactions mediated by the N-terminal domain of SIRT1 that increase SIRT1-dependent activities, decreasing acetylation of the NF-κB p65 and p53 proteins and increasing expression of *Pepck* (Figure 1E) and *Scd1* (Figure 4E). The physical interaction of NTERM with SIRT1 promotes the recruitment of a protein substrate NF-κB p65 into the enzyme-substrate complex, suggesting a mechanism for enhancing deacetylation of this protein.

Additionally, the NTERM domain interacts with DBC1, a negative regulator of SIRT1 activity (Kang et al., 2011; Kim et al., 2008; Zhao et al., 2008). The binding of DBC1 to the NTERM domain may additionally contribute to enhanced SIRT1 deacetylase activity. Several models can be envisioned for the regulation of SIRT1 enzymatic activity by the NTERM domain. The self-association of overexpressed NTERM domains through an interaction of motifs A and B is consistent with SIRT1 dimerization (Guo et al., 2012), although recombinant SIRT1 proteins purified from *E. coli* or Sf9 insect cells are monomeric (Lakshminarasimhan et al., 2013b). SIRT1 oligomerization may require additional posttranslational modifications or partner proteins that assemble into a multiprotein complex. Alternatively, the NTERM domain may function in cis to enhance the substrate-binding and deacetylase activities of the SIRT1 catalytic core. The interacting motifs A and B could pack together in the folded conformation of the NTERM domain, an interaction that could be stabilized in complex with a SIRT1 substrate. In addition, sites of phosphorylation within activating motifs A and B (Back et al., 2011; Kang et al., 2009; Nasrin et al., 2009) may affect the conformation of NTERM or its interactions with protein partners. It is also notable that motif B corresponds to a region of SIRT1 that is essential for activation of deacetylase activity by small molecules (Hubbard et al., 2013; Milne et al., 2007; Sinclair and Guarente, 2014).

Viral transduction of a 52-residue peptide corresponding to motif A of the NTERM domain improved glucose metabolism in
mice, coincident with overexpression of the peptide in the liver. The precise mechanism for these in vivo effects is still being investigated but may be related to the downregulation of NF-κB signaling by enhancing SIRT1 activity. So far, we have not been able to reconstitute the activation event of SIRT1 enzymatic activity in vitro upon addition of the purified recombinant NTERM domain, or the interaction of NTERM with the purified p53 Rel homology domain (residues 1–325). These results are consistent with the proposal that SIRT1 may be a part of a larger complex in which additional factors physically interact with NTERM, SIRT1, and substrate proteins in cells.

The active regulator of SIRT1 (AROS) enhances the SIRT1-dependent deacetylation of p53 by binding to the N-terminal domain of SIRT1 (Kim et al., 2007b) in a region (residues 114–217) that includes the activating motif B. It has been suggested that AROS may induce a conformational change of SIRT1 to stimulate deacetylase activity. One could envision positive regulators of SIRT1 activity stabilizing the interaction of motifs A and B to promote interactions with substrates, whereas DBC1 and negative regulators might stabilize an inactive conformation of the NTERM domain. To address such possibilities, it will be important to identify additional regulators of SIRT1 activity that may affect the conformation and/or the function of the NTERM domain. Structural studies of SIRT1 in complex with those regulatory proteins also will be important for understanding the mechanisms of regulating its enzymatic activity by proteins and by small molecules.

In conclusion, we have identified functional interactions of the SIRT1 NTERM domain and, specifically, the activating motifs A and B that enhance SIRT1-dependent activities in cells and in mice. Our results provide new insights into possible interventions that modulate SIRT1 activity through the binding interactions of the NTERM domain.

**EXPERIMENTAL PROCEDURES**

**Acetylation Levels of SIRT1 Substrates**

HepG2 cells were transfected with expression plasmids constructed from pCMV-HA and pCMV-Myc vectors (Clontech Laboratories) and encoding NF-κB p53 (Zhen et al., 2001) or p53, and SIRT1, NTERM, SIRT1(Δ221), or SIRT1(509–737) using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. Twenty-four hours later, the media were replaced with DMEM containing deacetylase inhibitors (10 μM nicotinamide) and cells were incubated overnight. Cells were placed with DMEM containing deacetylase inhibitors (10 μM nicotinamide) and/or a thio-acetyl lysine peptide (Sigma, anti-HA conjugated) according to the manufacturer’s protocol. Immunoprecipitation was performed as previously described (Revollo et al., 2004). To visualize SIRT1 peptides, the membranes were incubated with 10% glutaraldehyde (Sigma) in PBS for 30 min immediately before blocking. Primary antibodies included α-SIRT1 (1:1,000, Upstate Biotechnology), α-SIRT1(1:5,000, Sigma AS-16), α-hSIRT1(1:1,000, Abcam 19A7AB4), α-hSIRT1(1:1,000, Santa Cruz B-7), α-Myc (1:500, Clontech), α-NF-κB(1:1,000, Santa Cruz), α-tubulin (1:1,000, Santa Cruz), α-acetyl-NF-κB (1:1,000, Cell Signaling Technology), α-HA (1:1,000, Covance), α-Flag (1:1,000, Sigma), and α-acetyl-p53 (1:1,000, Cell Signaling Technology).

**Animal Experimentation**

All animal studies were approved by the Washington University Animal Studies Committee and performed in accordance with NIH guidelines. Reconstituent adenosines expressing GFP, SIRT1, or motif A (residues 1–52) proteins were prepared following the manufacturer’s protocol (Invitrogen AddEase) and used to infect 8–10-week-old male C57BL/6J mice (Taconic Laboratories) by tail vein injection of 5 x 10⁶ virus particles. After 4 days, IPGT was performed as previously described (Ramsey et al., 2008). Significant differences between groups of animals were determined using a one-way ANOVA with the Fisher’s PLSD test. For the detection of SIRT1 and the motif A peptide, mice were sacrificed by carbon dioxide asphyxiation after IPGT experiments. Livers were immediately collected, minced, and flash frozen in liquid nitrogen. Liver samples were homogenized in 2 x Laemmli sample buffer and boiled for 5 min. Samples were then centrifuged to remove debris and protein concentration was measured by the Bradford assay.

**Analytical Ultracentrifugation**

Experiments were performed at 25°C using a Beckman Instruments Optima XL-A analytical ultracentrifuge. For sedimentation velocity (SV) experiments, sample cells were loaded with 380 μl SIRT1 or 400 μl appropriate reference buffer and then centrifuged at 40,000 rpm. Data were collected in continuous mode at a wavelength of 280 nm and fitted to a continuous sedimentation coefficient [c] distribution model using the program SEDFIT (NIH). The sedimentation coefficient for SIRT1 was determined at a protein concentration of 40 μM in a buffer containing 50 mM NaCl, 50 mM HEPES (pH 8.0), 2 mM MgCl₂, 1 mM TCEP, and 0.1 mM EDTA. Sedimentation coefficients were determined in the presence of one or both substrates, NAD⁺ (1 mM) and/or a thio-acetyl lysine peptide (400 μM) corresponding to lysine 382 of the p53 protein, by monitoring absorbance at 295 nm.

For sedimentation equilibrium (SE) experiments, an Epon charcoal-filled six-sector centerpiece was used allowing three concentrations to be run simultaneously (5, 10, and 50 μM). Cells were loaded with 120 μl protein sample and 130 μl appropriate reference buffer. Optical absorbance values were monitored at 280 nm and runs were performed at speeds of 12,000, 15,000, 18,000, and 22,000 rpm until equilibrium was achieved (~24 hr determined from overlap of scans at 4-hr separation). Sedimentation equilibrium data were processed and analyzed using SEDFIT/SEDPHAT (Lobowitz et al., 2002), and values for partial specific volume and solvent density were calculated using SEDNTERP.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures and four figures and can be found with this article online at http://dx.doi.org/10.1016/j.cellrep.2015.02.036.
AUTHOR CONTRIBUTIONS


ACKNOWLEDGMENTS

We thank Roberto Galletto, James Doom, and Valentina Ghisays for advice and technical assistance; Darin Jones for the thioacetyl-lysine peptide; and members of the Ellenberger, Imai, and Janetka laboratories for valuable discussions. This work was supported by grants from the NIH (R01 GM052504 to T.E., R01 AG024150 to S.I., and R01 CA154697 to D.T.C.) and the Ellison Medical Foundation (to S.I.).

REFERENCES


